Coherus Aiming For More Than 10% Slice Of US Adalimumab Market
US-Based Firm Has December 2021 FDA Goal Date
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
You may also be interested in...
Coherus BioSciences is eyeing a potential late 2022/early 2023 timeline to introduce its proposed proprietary on-body injector device for its Udenyca pegfilgrastim biosimilar, after reporting positive results from a comparative clinical trial.
Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.
Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.